TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35297108
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination Cal/BD foam (calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g) for 4 weeks
Study: 35297108
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination Cal/BD foam (calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g)
Study: 35297108
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination Cal/BD foam
Study: 33849632
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline water injection
Study: 34592318
Drug: tPA bolus
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA bolus (50 mg tPA IV bolus followed by 7 days of heparin)
Study: 34592318
Drug: tPA drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA drip (50 mg tPA IV bolus, followed by tPA drip 2 mg/h plus heparin 500 units/h over 24 h)
Study: 34592318
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard‐of‐care treatment)
Study: 35119373
Drug: Smartphone-based data
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based data collection (weekly surveys, audio recordings, and passive location data)
Study: 34111416
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine (650 mg/m2 body surface area twice daily for 1 year)
Study: 34111416
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (observation)
Study: 33466627
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of sage combination (CogniviaTM)
Study: 35608600
Drug: Subcutaneous casirivimab
Normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous casirivimab and imdevimab antibody combination
Study: 32663179
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and integrative medicine
Study: 35567836
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose corticosteroids
Study: 35567836
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose corticosteroids
Study: 34628738
Drug: Flunarizine hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine hydrochloride capsule, 5 mg once a day
Study: 32125178
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/mL (Deg-100)
Study: 34487442
Drug: Cannabinoid-based medicines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid-based medicines
Study: 36251861
Drug: Tablet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based cognitive training (T-CT)
Study: 36428227
Drug: Sumac supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumac supplementation (500 mg, twice a day for 6 weeks)
Study: 36428227
Drug: Placebo (lactose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose, twice a day for 6 weeks)
Study: 34446475
Drug: Transient 100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient 100% oxygen administration
Study: 35219761
Drug: Non-insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin treatment
Study: 32403259
Drug: EXP-120 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXP-120 g/h
Study: 32403259
Drug: CON-90 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON-90 g/h
Study: 32403259
Drug: LOW-60 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW-60 g/h
Study: 35776749
Drug: Statistical models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statistical models adjusting for exposure time, covariates, and data augmentation
Study: 34992099
Drug: Weekly texts
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly texts instructing to study SRH topics
Study: 32437191
Drug: Structured Dyadic
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Dyadic Behavior Therapy (SDBT)
Study: 32437191
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control (Child-Centered Dyadic Therapy - CCDT)
Study: 34560315
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 0.25% levobupivacaine with 5 µg/mL epinephrine
Study: 34560315
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 0.25% levobupivacaine alone
Study: 32581042
Drug: Chemotherapy (Checkmate-064)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Checkmate-064)
Study: 34491805
Drug: SCTA01 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTA01 (5 mg/kg)
Study: 34491805
Drug: SCTA01 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTA01 (15 mg/kg)
Study: 34491805
Drug: SCTA01 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTA01 (30 mg/kg)
Study: 34491805
Drug: SCTA01 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTA01 (50 mg/kg)
Study: 34491805
Drug: SCTA01 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTA01 (5 to 50 mg/kg)
Study: 34340251
Drug: suvorexant 10-20
Normalized name: suvorexant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant 10-20 mg
Study: 32346816
Drug: Electronic modes
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic modes (handheld, tablet, IVR, web)
Study: 34464973
Drug: Thiotepa-based immunochemotherapy
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa-based immunochemotherapy (TIER) regimen including thiotepa 50 mg/m2, ifosfamide, etoposide, and rituximab for 2 cycles.
Study: 32383146
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) at 10 g kg‐1
Study: 32383146
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) at 50 g kg‐1
Study: 32383146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g kg‐1 GSE)
Study: 34967883
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg every 6 months)
Study: 35706460
Drug: Phase 1
Normalized name: Coxiella burnetii phase 1 IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 periodontal treatment (scaling and root planning)
Study: 32347899
Drug: Degarelix acetate
Normalized name: Degarelix acetate
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix acetate (120 mg, 2 subcutaneous injections)
Study: 35034024
Drug: REACT (renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACT (renal autologous cell therapy) administered via direct kidney parenchymal injection, 2 injections 6 months apart, with computed tomography guidance.
Study: 35034024
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (deferred treatment group) for 12 months before crossing over to receive REACT.
Study: 35034024
Drug: REACT (renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACT (renal autologous cell therapy)
Study: 32341386
Drug: Indoor incense
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor incense burning (self-reported use ≥ weekly over the past 5 years)
Study: 32671948
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation at a dose of 1.5 × 10^8 cfu/kg in heat-stressed broilers.
Study: 36212437
Drug: Zaltoprofen (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaltoprofen (480 mg/day) for 48 weeks
Study: 32899368
Drug: acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute treatment (wearing a mouthguard)
Study: 32899368
Drug: repeated treatments
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeated treatments (8 weeks follow‐up)
Study: 34486302
Drug: Alkaline solution
Normalized name: ALKALINE AROMATIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline solution washing (T4)
Study: 33355910
Drug: Tegoprazan 100
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 100 mg (multiple dose for 10 days)
Study: 32120018
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg testosterone
Study: 33662166
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (AHM)
Study: 36321501
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly for 12 months
Study: 36321501
Drug: Placebo-matched tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matched tablet
Study: 34563558
Drug: Crystalloid fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid fluid at 10 mL.kg‐1 of ideal body weight administered intravenously 30 minutes before BCP
Study: 32583773
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment T2 (6 billion cfu)
Study: 32583773
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment T1 (3 billion cfu)
Study: 34562410
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment strategies for MINOCA (specifics not provided)
Study: 32567586
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with polyethylene glycol (PEG)
Study: 32567586
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with sodium picosulfate
Study: 36266046
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid treatment with usual care
Study: 34819291
Drug: Arm 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Reminder texts and US$0.50 per day of medication taken
Study: 32250059
Drug: Psilocybin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0.3 to 0.6 mg/kg)
Study: 32250059
Drug: Supraclinical psilocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraclinical psilocin (60 ng/mL)
Study: 32522756
Drug: agalsidase‐beta (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: agalsidase‐beta (1.0 mg/kg), regular‐dose group, n=17
Study: 32522756
Drug: agalsidase‐alfa (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: agalsidase‐alfa (0.2 mg/kg), switch group, n=22
Study: 33963740
Drug: FPG ≥5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ≥5.1 mmol/L
Study: 34528692
Drug: 8-session telehealth
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session telehealth intervention for speech-language therapy
Study: 32384426
Drug: Sirolimus tablet
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus tablet (NPC‐12T)
Study: 34282872
Drug: Integrated low-intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated low-intensity intervention program (additional visits, health education, enhanced communication, weekly SMS reminders)
Study: 32543698
Drug: Feeling God's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeling God's presence daily
Study: 35396297
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg vaccine (Stage I)
Study: 35396297
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg vaccine (Stage I)
Study: 35396297
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg vaccine (Stage II)
Study: 35396297
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg vaccine (Phase II)
Study: 32445498
Drug: Fremanezumab 225
Normalized name: FREMANEZUMAB 225 mg in 1.5 mL SUBCUTANEOUS INJECTION [AJOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab 225 mg monthly
Study: 32445498
Drug: Fremanezumab 675
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab 675 mg quarterly
Study: 32433779
Drug: Crisaborole ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole ointment, 2%, applied twice daily
Study: 37385475
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogue (NA) treatment
Study: 32931877
Drug: Pegylated interferon‐alfa2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon‐alfa2a (PEG‐IFN) treatment
Study: 35693746
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose: 1 μg/kg over 10 min; maintenance dose: 0.2‐0.7 μg/kg/h)
Study: 35693746
Drug: Propofol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (loading dose: 75 μg/kg over 10 min; maintenance dose: 12.5‐75 μg/kg/min)
Study: 34476645
Drug: Reparixin (R)
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin (R) in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Study: 34476645
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Study: 33930329
Drug: IL-6 receptor
Normalized name: Humanised anti-IL-6 receptor monoclonal antibody
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IL-6 receptor antagonists
Study: 34555048
Drug: Advanced self-care
Normalized name: cetylpyridinium chloride Mouthwash [ACT Advanced Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced self-care with disinfectant using a custom-fabricated prescription tray applied twice a day
Study: 34554352
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) belimumab 10 mg/kg
Study: 34554352
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) belimumab 200 mg
Study: 33609174
Drug: Breakfast (ready‐to‐eat‐cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast (ready‐to‐eat‐cereal [RTEC] and milk, up to 70 g of cereal and 300 ml of milk)
Study: 33262202
Drug: ODM-203 400
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-203 400 mg/day
Study: 33739155
Drug: AndroForte5 (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroForte5 (testosterone 5.0% wt/vol, 100 mg/2 mL) cream (T) + supervised center-based exercise (Ex)
Study: 33287758
Drug: Extended chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended chemotherapy (>6 cycles, n = 52)
Study: 33287758
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (6 cycles, n = 83)
Study: 33287758
Drug: Extended chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended chemotherapy (>6 cycles)
Study: 33287758
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (6 cycles)
Study: 32633648
Drug: Eggshell membrane
Normalized name: eggshell membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eggshell membrane (EM) 300 mg daily for 12 weeks
Study: 32103645
Drug: Daily living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily living (control group)
Study: 35526530
Drug: Phentermine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (15 mg once daily)
Study: 616914772
Drug: PCVC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCVC therapy (paracentesis with central venous catheter, draining 1-2 L ascites every 1 or 2 days)
Study: 616914772
Drug: PCVC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCVC therapy
Study: 616914772
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diuretic therapy)
Study: 33823907
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm A offering HIV treatment irrespective of CD4 count
Study: 33823907
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm B following national guidelines for universal treatment
Study: 33116094
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy and phototherapy
Study: 34923602
Drug: Lyft 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyft 10 mg NP
Study: 37339396
Drug: LEMBOREXANT 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEMBOREXANT 5 mg (LEM5)
Study: 37339396
Drug: LEMBOREXANT 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEMBOREXANT 10 mg (LEM10)
Study: 33596356
Drug: Avacopan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacopan (30 mg twice daily)
Study: 33596356
Drug: Prednisone (tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (tapering schedule)
Study: 32915900
Drug: Hemosol B0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemosol B0 and potassium‐containing solution (MultiBic)
Study: 32915900
Drug: Phosphate‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate‐ and potassium‐containing solution (Phoxilium), Hemosol B2, Prismasol 2, and Prismasol 4
Study: 33118421
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of NZBC extract (210 mg of anthocyanins, CurraNZ™) for 14 days
Study: 36178918
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation for 15 days
Study: 35630085
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clindamycin every 8 h for 5 days
Study: 35630085
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clindamycin every 8 h for 5 days
Study: 35630085
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clindamycin every 12 h for 5 days
Study: 34037885
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (50 mg/kg/day for 10 weeks)
Study: 34844625
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy plus home stretching exercises
Study: 34369667
Drug: PF-06730512 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06730512 (up to 1000 mg IV single ascending dose)
Study: 34369667
Drug: PF-06730512 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06730512 (up to 400 mg SC multiple ascending doses)
Study: 34369667
Drug: PF-06730512 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06730512 (up to 1000 mg IV multiple ascending doses)
Study: 34543419
Drug: Relative weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Relative weekly change of progression >10% in running volume and progression in running pace
Study: 34543419
Drug: Absolute weekly
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute weekly change of progression >5 km in running volume and progression in running pace
Study: 34671676
Drug: Oral synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral synthetic vitamin E (400 IU/day) for eight weeks
Study: 33874898
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg IV aminophylline (Group A1)
Study: 33874898
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg IV aminophylline (Group A2)
Study: 34244155
Drug: ω‐3‐FA (3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3‐FA (3.25 g/day combined EPA and DHA)
Study: 34363762
Drug: Avelumab maintenance
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab maintenance (10 mg/kg intravenously every 2 weeks)
Study: 34363762
Drug: Avelumab combination
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab combination (10 mg/kg intravenously every 3 weeks)
Study: 34363762
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy followed by observation)
Study: 35964041
Drug: LH-based flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-based flexible GnRH antagonist protocol
Study: 35964041
Drug: Traditional flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional flexible GnRH antagonist protocol
Study: 33982405
Drug: Difelikefalin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin 1.0 mcg/kg i.v.
Study: 33982405
Drug: Difelikefalin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin 5.0 mcg/kg i.v.
Study: 32241693
Drug: Adjuvant targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant targeted therapy (TT)
Study: 32241693
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant targeted therapy (TT)